smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 2500 ml biofine bag
fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion1950 ml biofine bag
fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 1400 ml biofine bag
fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
smofkabiven low osmo amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 850 ml biofine bag
fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; egg lecithin; glycerol; sodium oleate; sodium hydroxide; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
numeta g13%e preterm emulsion for infusion g13e
baxter healthcare limited - glucose; amino acids - emulsion for infusion - glucose 50 %; amino acids 5.9 % - blood substitutes and perfusion solutions
numeta g13%e preterm, emulsion for infusion
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose, amino acids - emulsion for infusion - glucose 50 % amino acids 5.9 % - blood substitutes and perfusion solutions
acetaminophen and codeine phosphate- acetaminophen and codeine phosphate tablet
nucare pharmaceuticals, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not provided adequate analgesia, or are not expected to provide adequate analgesia - have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated in patients with: - patients with significant respiratory depression [see warnings]. - patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. - postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy [see warnings]
acetaminophen and codeine phosphate tablet
contract pharmacy services-pa - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not provided adequate analgesia, or are not expected to provide adequate analgesia - have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated in patients with: - patients with significant respiratory depression [see warnings]. - patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. - postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy [
acetaminophen and codeine phosphate tablet
proficient rx lp - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] acetaminophen and codeine phosphate tablets are contraindicated in patients with: controlled substance acetaminophen and codeine phosphate tablet contains acetaminophen and codeine phosphate, a schedule cii controlled substance. abuse acetaminophen and codeine phosphate tablet contains codeine, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydrormorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. acetaminophen and codeine phosphate tablets can be abused and is subject to
acetaminophen and codeine phosphate tablet
ncs healthcare of ky, llc dba vangard labs - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not provided adequate analgesia, or are not expected to provide adequate analgesia - have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated in patients with: - patients with significant respiratory depression [see warnings]. - patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. - postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy [see warnings]